Skip to main content
  • AACR Journals
    • Blood Cancer Discovery
    • Cancer Discovery
    • Cancer Epidemiology, Biomarkers & Prevention
    • Cancer Immunology Research
    • Cancer Prevention Research
    • Cancer Research
    • Clinical Cancer Research
    • Molecular Cancer Research
    • Molecular Cancer Therapeutics

AACR logo

  • Register
  • Log in
  • My Cart
Advertisement

Main menu

  • Home
  • About
    • The Journal
    • AACR Journals
    • Subscriptions
    • Permissions and Reprints
    • Reviewing
  • Articles
    • OnlineFirst
    • Current Issue
    • Past Issues
    • Meeting Abstracts
    • Collections
      • COVID-19 & Cancer Resource Center
      • Focus on Radiation Oncology
      • Novel Combinations
      • Reviews
      • Editors' Picks
      • "Best of" Collection
  • For Authors
    • Information for Authors
    • Author Services
    • Best of: Author Profiles
    • Submit
  • Alerts
    • Table of Contents
    • Editors' Picks
    • OnlineFirst
    • Citation
    • Author/Keyword
    • RSS Feeds
    • My Alert Summary & Preferences
  • News
    • Cancer Discovery News
  • COVID-19
  • Webinars
  • Search More

    Advanced Search

  • AACR Journals
    • Blood Cancer Discovery
    • Cancer Discovery
    • Cancer Epidemiology, Biomarkers & Prevention
    • Cancer Immunology Research
    • Cancer Prevention Research
    • Cancer Research
    • Clinical Cancer Research
    • Molecular Cancer Research
    • Molecular Cancer Therapeutics

User menu

  • Register
  • Log in
  • My Cart

Search

  • Advanced search
Molecular Cancer Therapeutics
Molecular Cancer Therapeutics
  • Home
  • About
    • The Journal
    • AACR Journals
    • Subscriptions
    • Permissions and Reprints
    • Reviewing
  • Articles
    • OnlineFirst
    • Current Issue
    • Past Issues
    • Meeting Abstracts
    • Collections
      • COVID-19 & Cancer Resource Center
      • Focus on Radiation Oncology
      • Novel Combinations
      • Reviews
      • Editors' Picks
      • "Best of" Collection
  • For Authors
    • Information for Authors
    • Author Services
    • Best of: Author Profiles
    • Submit
  • Alerts
    • Table of Contents
    • Editors' Picks
    • OnlineFirst
    • Citation
    • Author/Keyword
    • RSS Feeds
    • My Alert Summary & Preferences
  • News
    • Cancer Discovery News
  • COVID-19
  • Webinars
  • Search More

    Advanced Search

Small Molecule Therapeutics

Activity of a Novel Hec1-Targeted Anticancer Compound against Breast Cancer Cell Lines In Vitro and In Vivo

Lynn Y.L. Huang, Chia-Chi Chang, Ying-Shuan Lee, Jia-Ming Chang, Jiann-Jyh Huang, Shih-Hsien Chuang, Kuo-Jang Kao, Gillian M.G. Lau, Pei-Yi Tsai, Chia-Wei Liu, Her-Sheng Lin and Johnson Y.N. Lau
Lynn Y.L. Huang
1Taivex Therapeutics Corporation, Taipei; and 2Development Center for Biotechnology, New Taipei City, Taiwan
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Chia-Chi Chang
1Taivex Therapeutics Corporation, Taipei; and 2Development Center for Biotechnology, New Taipei City, Taiwan
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Ying-Shuan Lee
1Taivex Therapeutics Corporation, Taipei; and 2Development Center for Biotechnology, New Taipei City, Taiwan
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Jia-Ming Chang
1Taivex Therapeutics Corporation, Taipei; and 2Development Center for Biotechnology, New Taipei City, Taiwan
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Jiann-Jyh Huang
1Taivex Therapeutics Corporation, Taipei; and 2Development Center for Biotechnology, New Taipei City, Taiwan
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Shih-Hsien Chuang
1Taivex Therapeutics Corporation, Taipei; and 2Development Center for Biotechnology, New Taipei City, Taiwan
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Kuo-Jang Kao
1Taivex Therapeutics Corporation, Taipei; and 2Development Center for Biotechnology, New Taipei City, Taiwan
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Gillian M.G. Lau
1Taivex Therapeutics Corporation, Taipei; and 2Development Center for Biotechnology, New Taipei City, Taiwan
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Pei-Yi Tsai
1Taivex Therapeutics Corporation, Taipei; and 2Development Center for Biotechnology, New Taipei City, Taiwan
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Chia-Wei Liu
1Taivex Therapeutics Corporation, Taipei; and 2Development Center for Biotechnology, New Taipei City, Taiwan
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Her-Sheng Lin
1Taivex Therapeutics Corporation, Taipei; and 2Development Center for Biotechnology, New Taipei City, Taiwan
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Johnson Y.N. Lau
1Taivex Therapeutics Corporation, Taipei; and 2Development Center for Biotechnology, New Taipei City, Taiwan
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
DOI: 10.1158/1535-7163.MCT-13-0700 Published June 2014
  • Article
  • Figures & Data
  • Info & Metrics
  • PDF
Loading

Article Figures & Data

Figures

  • Tables
  • Additional Files
  • Figure 1.
    • Download figure
    • Open in new tab
    • Download powerpoint
    Figure 1.

    TAI-95 targets the Hec1/Nek2 pathway. A, MDA-MB-231 cells were treated with DMSO (vehicle control) or 1 μmol/L TAI-95 for 3 hours, lysed, and lysates immunoprecipitated by Nek2 antibody to see co-immunoprecipitated Hec1. Control IgG was used as control antibody for immunoprecipitation. Rbt, rabbit; Ms, mouse. B, cells were incubated for the indicated time points with DMSO or TAI-95 and immunoblotted for levels of Hec1 and Nek2 protein expression. Q.Nek2, quantification by ImageJ (inverted mean, ×1,000). C, MDA-MB-468 cells were grown on chamber slides and treated with DMSO or TAI-95 for 48 hours. After fixation, cells were stained with tubulin antibody and DAPI to stain for microtubules and DNA, respectively, and cells (>500) were counted for presence of chromosomal abnormality and expressed as percentage counted. *, P < 0.05; **, P < 0.01, by 2-tailed t test.

  • Figure 2.
    • Download figure
    • Open in new tab
    • Download powerpoint
    Figure 2.

    TAI-95 leads to apoptotic cell death in breast cancer cell lines. A, synchronized cancer cells treated with DMSO, 1 μmol/L TAI-95, or 20 μmol/L topotecan were immunoblotted for the cleavage of PARP. B, cells were treated with 1 μmol/L TAI-95 for 48 hours, stained for Annexin V and PI, and then analyzed with FACS. C, cells were treated with 1 μmol/L TAI-95 for 24 hours, stained for DNA content with PI, and analyzed with FACS, with the exception of MCF7, which was treated with 50 nmol/L TAI-95 for 72 hours. Topo, topotecan.

  • Figure 3.
    • Download figure
    • Open in new tab
    • Download powerpoint
    Figure 3.

    TAI-95 inhibits tumor growth in breast cancer xenograft mouse models. BT474 breast cancer xenograft model in nude mice were used to test the in vivo efficacy of TAI-95. When tumor size reached 200 mm3, a twice daily, 28-day oral dosing treatment of TAI-95 was initiated. Tumor size (A) and body weights (B) were measured. **, P < 0.01; ***, P < 0.001, by 2-tailed t test.

  • Figure 4.
    • Download figure
    • Open in new tab
    • Download powerpoint
    Figure 4.

    TAI-95 inhibits large tumor growth and does not lead to resistance. BT474 (triple-positive) breast cancer xenograft model in nude mice was used to test the in vivo re-dosing efficacy of TAI-95. TAI-95 dosing was re-initiated after 2 weeks of non-dosing period and restarted on day 42 lasting for another 28 days. Vehicle group mice were sacrificed according to animal protocols and tumor volume postulated with linear assumption. A, tumor volume plotted against time. B, starting tumor size was plotted against treatment dose with circles with size and numbers indicating growth rates obtained at the end of the 28-day treatment period. **, P < 0.01; ***, P < 0.001; ****, P < 0.0001, by 2-tailed t test.

  • Figure 5.
    • Download figure
    • Open in new tab
    • Download powerpoint
    Figure 5.

    TAI-95 potency in MDR lines. A, MDR cells treated with TAI-95 for 96 hours and quantitated with MTS assay to generate GI50. MES-SA/Dx5 (uterine sarcoma), NCI/ADR-RES (ovarian carcinoma), and K562R (leukemia) were tested and 2 paclitaxel-resistant breast cancer cell lines are included as reference. B, cells were treated with 50 nmol/L TAI-95 for the indicated time period, collected, RNA extracted, and analyzed with quantitative PCR. Glyceraldehyde-3-phosphate dehydrogenase (GAPDH) was used as loading control and mRNA expression is presented as percentage of DMSO (vehicle control). *, P < 0.05; **, P < 0.01; ***, P < 0.001.

  • Figure 6.
    • Download figure
    • Open in new tab
    • Download powerpoint
    Figure 6.

    TAI-95 downregulates MDR expression. A and B, cells were treated with 100 nmol/L TAI-95 for the indicated time period, collected, RNA extracted, and analyzed with quantitative PCR. Glyceraldehyde-3-phosphate dehydrogenase (GAPDH) was used as loading control and mRNA expression is presented as percentage of DMSO (vehicle control). C, cells were pretreated with DMSO, 33 nmol/L (lo) or 166 nmol/L (hi) TAI-95 for 6 hours and then treated with the indicated cytotoxic agent for 72 hours and quantitated with MTS assay. Right, the RNA level of Pgp at 6 hours. *, P < 0.05; **, P < 0.01; ***, P < 0.001, by 2-tailed t test.

  • Figure 7.
    • Download figure
    • Open in new tab
    • Download powerpoint
    Figure 7.

    Clinical correlation of TAI-95 target Hec1 in breast cancer. A, representative blots of Hec1 protein expression in breast cancer cell lines. B, average values of quantitated Hec1 protein expression. C, Hec1 gene expression among different molecular subtypes of breast cancer based on GSE20685 dataset. D, one-way cluster analysis of Hec1 (NDC80) and 8 other genes known to associate with Hec1 was performed. A heatmap was drawn according to breast cancer molecular subtypes. Results show differential expression of Hec1 and associated genes among different molecular subtypes of breast cancer.

Tables

  • Figures
  • Additional Files
  • Table 1.

    GI50 values of TAI-95 in various breast cancer lines

    MDA-MB-231MDA-MB-468T47DHs578TZR-75-1MCF7HCC1954BT474ZR-75-30MDA-MB-453MDA-MB-361
    Paclitaxel3.00 nmol/L2.38 nmol/L3.19 nmol/L7.99 nmol/L>10 μmol/L>10 μmol/L>10 μmol/L5.40 nmol/L>10 μmol/L1.71 nmol/L>10 μmol/L
    Doxorubicin213.80 nmol/L28.27 nmol/L7.22 nmol/L423.34 nmol/L134.87 nmol/L>10 μmol/L509.20 nmol/L158.56 nmol/L>10 μmol/L114.26 nmol/L>10 μmol/L
    Topotecan346.73 nmol/L10.71 nmol/L9.43 nmol/L4513 nmol/L48.39 nmol/L>10 μmol/L675.90 nmol/L>10 μmol/L2334 nmol/L91.39 nmol/L303.92 nmol/L
    Gemcitabine6.44 nmol/L5.04 nmol/L10.35 nmol/L>10 μmol/L5.23 nmol/L>10 μmol/L>10 μmol/L>10 μmol/L>10 μmol/LND>50 μmol/L
    Irinotecan>10 μmol/L1997 nmol/L724.70 nmol/L>50 μmol/L>10 μmol/L>10 μmol/L>10 μmol/L>50 μmol/L>10 μmol/LND>50 μmol/L
    Gefinitib>10 μmol/L9093 nmol/L>10 μmol/L>10 μmol/L>10 μmol/L>10 μmol/L>10 μmol/L774.00 nmol/L4820 nmol/LND>10 μmol/L
    Cisplatin>10 μmol/L>10 μmol/L>50 μmol/L>10 μmol/L>50 μmol/L>50 μmol/L>10 μmol/L>50 μmol/L>50 μmol/LND>50 μmol/L
    Cyclophosphamide>500 μmol/L>500 μmol/L>500 μmol/L>50 μmol/L>50 μmol/L>50 μmol/L>50 μmol/L>50 μmol/L>50 μmol/LND>50 μmol/L
    KX0143.41 nmol/L26.50 nmol/L51.98 nmol/L37.79 nmol/L>10 μmol/L>10 μmol/L>10 μmol/L>10 μmol/L>10 μmol/L53.47 nmol/L32.18 nmol/L
    Sorafenib3760 nmol/L3172 nmol/L1730 nmol/L7252 nmol/L4541 nmol/L>10 μmol/L4661 nmol/L4638 nmol/L4074 nmol/L3461 nmol/L4441 nmol/L
    Sunitinib>10 μmol/L>10 μmol/L>10 μmol/L>10 μmol/L>10 μmol/L>10 μmol/L>10 μmol/L>10 μmol/L>10 μmol/LND>10 μmol/L
    TAI-9516.48 nmol/L22.21 nmol/L14.29 nmol/L43.39 nmol/L52.35 nmol/L39.17 nmol/L25.46 nmol/L73.65 nmol/L25.47 nmol/L> 10 μmol/L> 10 μmol/L

    Abbreviation: ND, not determined.

    Additional Files

    • Figures
    • Tables
    • Supplementary Data

      Files in this Data Supplement:

      • Supplementary Materials and Methods, Supplementary Table 1, and Supplementary Figure Legends - PDF - 126K, Includes the methods for preparation of TAI-95, drug-drug synergy experiments, and preliminary subacute toxicology, Table S1: Combination index of TAI-95 with anticancer agents, and supplementary figure legends.
      • Supplementary Figures 1 through 6 - PDF - 1333K, Figure S1. Summary of structural modifications. Figure S2. Hec1 localization. Figure S3. Activation of apoptosis. Figure S4. Subacute toxicity study: histological sections. Figure S5. Subacute toxicity study: organ weight and blood indices. Figure S6. Additional breast cancer xenograft mouse models.
    PreviousNext
    Back to top
    Molecular Cancer Therapeutics: 13 (6)
    June 2014
    Volume 13, Issue 6
    • Table of Contents
    • Table of Contents (PDF)
    • About the Cover

    Sign up for alerts

    View this article with LENS

    Open full page PDF
    Article Alerts
    Sign In to Email Alerts with your Email Address
    Email Article

    Thank you for sharing this Molecular Cancer Therapeutics article.

    NOTE: We request your email address only to inform the recipient that it was you who recommended this article, and that it is not junk mail. We do not retain these email addresses.

    Enter multiple addresses on separate lines or separate them with commas.
    Activity of a Novel Hec1-Targeted Anticancer Compound against Breast Cancer Cell Lines In Vitro and In Vivo
    (Your Name) has forwarded a page to you from Molecular Cancer Therapeutics
    (Your Name) thought you would be interested in this article in Molecular Cancer Therapeutics.
    CAPTCHA
    This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.
    Citation Tools
    Activity of a Novel Hec1-Targeted Anticancer Compound against Breast Cancer Cell Lines In Vitro and In Vivo
    Lynn Y.L. Huang, Chia-Chi Chang, Ying-Shuan Lee, Jia-Ming Chang, Jiann-Jyh Huang, Shih-Hsien Chuang, Kuo-Jang Kao, Gillian M.G. Lau, Pei-Yi Tsai, Chia-Wei Liu, Her-Sheng Lin and Johnson Y.N. Lau
    Mol Cancer Ther June 1 2014 (13) (6) 1419-1430; DOI: 10.1158/1535-7163.MCT-13-0700

    Citation Manager Formats

    • BibTeX
    • Bookends
    • EasyBib
    • EndNote (tagged)
    • EndNote 8 (xml)
    • Medlars
    • Mendeley
    • Papers
    • RefWorks Tagged
    • Ref Manager
    • RIS
    • Zotero
    Share
    Activity of a Novel Hec1-Targeted Anticancer Compound against Breast Cancer Cell Lines In Vitro and In Vivo
    Lynn Y.L. Huang, Chia-Chi Chang, Ying-Shuan Lee, Jia-Ming Chang, Jiann-Jyh Huang, Shih-Hsien Chuang, Kuo-Jang Kao, Gillian M.G. Lau, Pei-Yi Tsai, Chia-Wei Liu, Her-Sheng Lin and Johnson Y.N. Lau
    Mol Cancer Ther June 1 2014 (13) (6) 1419-1430; DOI: 10.1158/1535-7163.MCT-13-0700
    del.icio.us logo Digg logo Reddit logo Twitter logo CiteULike logo Facebook logo Google logo Mendeley logo
    • Tweet Widget
    • Facebook Like
    • Google Plus One

    Jump to section

    • Article
      • Abstract
      • Introduction
      • Materials and Methods
      • Results
      • Discussion
      • Disclosure of Potential Conflicts of Interest
      • Authors' Contributions
      • Grant Support
      • Acknowledgments
      • Footnotes
      • References
    • Figures & Data
    • Info & Metrics
    • PDF
    Advertisement

    Related Articles

    Cited By...

    More in this TOC Section

    • Discovery of a Novel Anticancer Therapeutic
    • eFT226, a Selective Inhibitor of eIF4A-Mediated Translation
    • Peptide Inhibiting Breast Cancer by Disrupting SND1–MTDH
    Show more Small Molecule Therapeutics
    • Home
    • Alerts
    • Feedback
    • Privacy Policy
    Facebook  Twitter  LinkedIn  YouTube  RSS

    Articles

    • Online First
    • Current Issue
    • Past Issues
    • Meeting Abstracts

    Info for

    • Authors
    • Subscribers
    • Advertisers
    • Librarians

    About MCT

    • About the Journal
    • Editorial Board
    • Permissions
    • Submit a Manuscript
    AACR logo

    Copyright © 2021 by the American Association for Cancer Research.

    Molecular Cancer Therapeutics
    eISSN: 1538-8514
    ISSN: 1535-7163

    Advertisement